Duprey Lauren Rusckowski's Form 4 filing
Takeda Pharmaceutical Co LtdTAK · filed Sep 15, 2026
- Accession no.
- 0001395064-26-000340
- Filed
- Sep 15, 2026, 9:12 PM ET
- Trade date
- Sep 14, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $640.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Duprey Lauren RusckowskiCIK 0001977746 | Officer (Chief Transformation Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | American Depositary Shares | SSaleDisposed | −34,535 | $18.54 | −$640,278.9 | 191,522 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.